Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCZ484 in Healthy Subjects and Subjects With Mild Hypertension
NCT06905327Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- RNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of QCZ484 in hypertension (HTN) (9 arms), sponsored by Novartis. Primary endpoints: Number of adverse events at 8 weeks and Number of participants with abnormalities in any laboratory parameter at 8 weeks. Started Mar 2023; status: completed.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06905327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905327.